Opus Genetics, Inc. IRD
4.01 USD -0.26 (-6.21%)
At closeNov 5, 2026, 4:41 PM EST
3.99 -0.01 -0.37%
After hours · Nov 5, 4:41 PM ET
3.80 Day range 4.26
1.70 52-week range 7.07
- YTD
- +99.25%
- 1 year
- +88.92%
News
globenewswire.com Opus Genetics Completes Dosing in Cohort 2 of Phase 1/2 Clinical Trial of OPGx-BEST1 Gene Therapy for Inherited Retinal Diseases RESEARCH TRIANGLE PARK, N.C., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene…
globenewswire.com Opus Genetics to Present at the Guggenheim Annual Healthcare Innovation Conference RESEARCH TRIANGLE PARK, N.C., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene…
globenewswire.com Opus Genetics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) RESEARCH TRIANGLE PARK, N.C., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent…
globenewswire.com Opus Genetics Appoints Dr. Andrew Murphy as Chief Scientific Officer and Jamie Lynne Hart as Executive Director, Executive Operations RESEARCH TRIANGLE PARK, N.C., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene…
marketbeat.com Opus Genetics Eyes 2029 Runway as Presbyopia Drop Wins FDA Approval Opus Genetics NASDAQ: IRD outlined commercialization expectations for its newly approved presbyopia eye drop, progress across its inherited retinal disease gene therapy pipeline and its funding…
benzinga.com FDA Clears Opus Genetics’ IND Application For Opgx-RDH12, Investigational Gene Therapy For Treatment Of RDH12-Associated Leber Congenital Amaurosis FDA clearance enables clinical development of OPGx-RDH12 for RDH12-associated Leber congenital amaurosis, a rare inherited retinal disease that causes progressive vision loss beginning in early…
globenewswire.com Opus Genetics Announces FDA Clearance of IND Application for OPGx-RDH12 Gene Therapy for Inherited Childhood Blindness FDA clearance enables clinical development of OPGx-RDH12 for RDH12-associated Leber congenital amaurosis, a rare inherited retinal disease that causes progressive vision loss beginning in early…
benzinga.com Opus Genetics Receives FDA Approval For Its Supplemental New Drug Application For Phentolamine Ophthalmic Solution 0.75% To Treat Presbyopia In Adults Opus Genetics, Inc. (NASDAQ:IRD) ("Opus Genetics" or the "Company"), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with
globenewswire.com Opus Genetics Announces FDA Approval of Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia FDA expands the approved use of phentolamine ophthalmic solution 0.75% to include age-related near vision impairment, which affects millions of adults in the United States Approval supported by…
benzinga.com Citizens Reiterates Market Outperform on Opus Genetics, Maintains $17 Price Target Citizens analyst Jonathan Wolleben reiterates Opus Genetics (NASDAQ:IRD) with a Market Outperform and maintains $17 price target.
benzinga.com Why Alcoa Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket Alcoa shares rose after Q3 earnings beat estimates; Rubico and others surged, while Nuburu, Jaguar Health and other stocks fell premarket.- benzinga.com Opus Genetics Presents Clinical Findings From OPGx-BEST1 And OPGx-LCA5 Gene Therapy Programs At Retina In Rio 2026; Phase 3 Clinical Trial Dosing For OPGx-LCA5 Expected In Q4 Of 2026 OPGx-BEST1 showed improved retinal sensitivity in 75% of evaluable participants in the initial low-dose Cohort 1 of the Company’s Phase 1/2 clinical trial, supporting further clinical developmentNew…
globenewswire.com Opus Genetics Presents Positive Clinical Data from OPGx-BEST1 and OPGx-LCA5 Gene Therapy Programs at Retina in Rio 2026 OPGx-BEST1 showed improved retinal sensitivity in 75% of evaluable participants in the initial low-dose Cohort 1 of the Company's Phase 1/2 clinical trial, supporting further clinical development New…
globenewswire.com Opus Genetics to Present at the Chardan Annual Healthcare Conference RESEARCH TRIANGLE PARK, N.C., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene…
defenseworld.net Opus Genetics, Inc. (NASDAQ:IRD) Receives Consensus Recommendation of “Moderate Buy” from Brokerages Opus Genetics, Inc. (NASDAQ: IRD - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the eighteen ratings firms that are covering the company, Marketbeat reports. One…
defenseworld.net Squarepoint Ops LLC Takes $1.36 Million Position in Opus Genetics, Inc. $IRD Squarepoint Ops LLC purchased a new stake in Opus Genetics, Inc. (NASDAQ: IRD) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange…
seekingalpha.com Opus Genetics: A Resounding Study Success Merits A Higher Valuation Opus Genetics receives a Buy rating following >30% stock surge on positive Phase 1/2 data for OPGx-BEST1 in BEST1-related retinal diseases. OPGx-BEST1 showed clinically meaningful visual improvements…
seekingalpha.com Opus Genetics, Inc. (IRD) Discusses Topline Results From Cohort 1 of BEST1 Phase I/II Gene Therapy Trial Transcript Opus Genetics, Inc. (IRD) Discusses Topline Results From Cohort 1 of BEST1 Phase I/II Gene Therapy Trial Transcript
benzinga.com Wedbush Maintains Outperform on Opus Genetics, Raises Price Target to $13 Wedbush analyst Yun Zhong maintains Opus Genetics (NASDAQ:IRD) with a Outperform and raises the price target from $10 to $13.
benzinga.com Oppenheimer Maintains Outperform on Opus Genetics, Raises Price Target to $20 Oppenheimer analyst Andreas Argyrides maintains Opus Genetics (NASDAQ:IRD) with a Outperform and raises the price target from $10 to $20.- benzinga.com HC Wainwright & Co. Reiterates Buy on Opus Genetics, Maintains $8 Price Target HC Wainwright & Co. analyst Matthew Caufield reiterates Opus Genetics (NASDAQ:IRD) with a Buy and maintains $8 price target.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Opus Genetics (NASDAQ:IRD) shares increased by 31.7% to $5.71 during Wednesday's regular session. The company's market cap stands at $361.0 million. bioAffinity Technologies (NASDAQ:BIAF)…
benzinga.com Crude Oil Jumps Over 3%; Core & Main Posts Upbeat Q2 Earnings U.S. stocks fell Wednesday as energy rose and discretionary slumped; Signet and Opus surged, while ServiceTitan plunged. Oil jumped 3.6%.
benzinga.com Gene Therapy at Lower Dose Shows Vision Improvements, Opus Genetics Says Opus Genetics, Inc. (NASDAQ:IRD) stock is surging on Wednesday after the company reported positive three- and six-month results from the low-dose first cohort of its Phase 1/2 BIRD-1 trial of…
benzinga.com Gene Therapy at Lower Dose Shows Vision Improvements, Opus Genetics Says Opus Genetics posts positive Phase 1/2 trial results for OPGx-BEST1 and aligns with the FDA on Phase 3 plans for 2027.
benzinga.com Caleres Posts Upbeat Q2 Earnings, Joins Opus Genetics, Flotek Industries And Other Big Stocks Moving Higher On Wednesday U.S. stocks fell, but Caleres surged 14% on strong results and higher guidance. Opus Genetics, Signet and Oddity also posted big gains.
benzinga.com Dow Tumbles 350 Points; Signet Jewelers Shares Jump Following Upbeat Q2 Earnings U.S. stocks fell Wednesday, led by a 350-point Dow drop. Signet surged on strong earnings; oil, gold and silver prices climbed.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers Modular Medical (NASDAQ:MODD) shares increased by 11.3% to $3.14 during Wednesday's pre-market session. The market value of their outstanding shares is at $22.9 million. InnovAge Holding…
benzinga.com Opus Genetics Announces Results From Low-Dose Cohort 1 Of BIRD-1, Ongoing Phase 1/2 Clinical Trial Evaluating Opgx-BEST1 Showing Favorable Safety, Tolerability Profile With No Serious Adverse Events Or Dose-Limiting Toxicities Observed OPGx-BEST1 demonstrated a favorable safety and tolerability profile with no serious adverse events or dose-limiting toxicities observed All five participants demonstrated clinically meaningful…
globenewswire.com Opus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of OPGx-BEST1 and Successful FDA Type C Meeting with Potential Phase 3 Dosing in 2027 OPGx-BEST1 demonstrated a favorable safety and tolerability profile with no serious adverse events or dose-limiting toxicities observed All five participants demonstrated clinically meaningful…
defenseworld.net Analysts Set Opus Genetics, Inc. (NASDAQ:IRD) PT at $10.69 Opus Genetics, Inc. (NASDAQ: IRD - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the eighteen analysts that are presently covering the firm, MarketBeat Ratings…- benzinga.com Opus Genetics Plans To Present Topline Clinical Data From Cohort 1 Of Its Phase 1/2 Study Of OPGx-BEST1 During Investor Conference Call And Webcast On September 9 Topline data from Phase 1/2 Cohort 1 of OPGx-BEST1 gene therapy program to be presented during investor conference call and webcast on September 9 at 8:00 a.m. ETFull clinical dataset and additional…
globenewswire.com Opus Genetics to Present OPGx-BEST1 Cohort 1 Clinical Data in Investor Webcast and at Upcoming Leading Ophthalmology Conferences Topline data from Phase 1/2 Cohort 1 of OPGx-BEST1 gene therapy program to be presented during investor conference call and webcast on September 9 at 8:00 a.m. ET Full clinical dataset and additional…
defenseworld.net ADAR1 Capital Management LLC Takes $7.33 Million Position in Opus Genetics, Inc. $IRD ADAR1 Capital Management LLC acquired a new position in Opus Genetics, Inc. (NASDAQ: IRD) during the second quarter, according to its most recent filing with the Securities and Exchange Commission…
globenewswire.com Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) RESEARCH TRIANGLE PARK, N.C., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent…
benzinga.com RBC Capital Maintains Outperform on Opus Genetics, Lowers Price Target to $9 RBC Capital analyst Lisa Walter maintains Opus Genetics (NASDAQ:IRD) with a Outperform and lowers the price target from $10 to $9.- benzinga.com Opus Genetics Files Prospectus To Sell $300M Mixed Securities Shelf Including 34.5M Shares Common StockPreferred StockDebt SecuritiesWarrantsUnitsand up to 34,449,749 Shares of Common Stock Issuable Upon Exercise ofWarrants and Pre-Funded Warrants Offered, from time to time, by…
zacks.com Opus Genetics, Inc. (IRD) Reports Q2 Loss, Lags Revenue Estimates Opus Genetics, Inc. (IRD) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to a loss of $0.12 per share a year ago.- benzinga.com Opus Genetics Q2 EPS $(0.14) Beats $(0.16) Estimate, Sales $755.000K Miss $2.470M Estimate Opus Genetics (NASDAQ:IRD) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.16) by 12.5 percent. This is a 16.67 percent decrease over losses of $(0.12)…
- benzinga.com Opus Genetics Says Last Patient Enrolled In Registrational Phase 3 Clinical Trial Evaluating OPGx-LCA5, Investigational Gene Therapy For LCA5-Associated Inherited Retinal Disease Topline six-month efficacy data expected by end of 2027Phase 3 study follows FDA alignment on registrational trial design through Rare Disease Evidence Principles (RDEP) programOpus Genetics may…
benzinga.com Top 3 Health Care Stocks That May Rocket Higher In July Health care sector oversold - buying opportunities in undervalued companies. RSI compares stock strength on up/down days, below 30 is oversold.
benzinga.com Opus Genetics Expects To Announce Three-month Topline Data From Cohort 1 Of Phase 1/2 Trial Of OPGx-BEST1 For Best Vitelliform Macular Dystrophy Or Autosomal-recessive Bestrophinopath, During The Second Week Of September 2026 Opus Genetics, Inc. (NASDAQ:IRD) (the "Company", "Opus Genetics" or "Opus"), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in
benzinga.com Opus Genetics Aligns With FDA In A Type B Rare Disease Meeting On Design Of Its Registrational Phase 3 Clinical Trial Evaluating OPGX-lCA5 For Early-Onset Severe Inherited Retinal Dystrophy Opus Genetics has received the meeting minutes from the Type B meeting confirming several key elements of the trial. The Phase 3 study is expected to enroll eight participants who are able to…- benzinga.com Opus Genetics Set To Join Russell 3000, 2000, Microcap Indexes, Effective June 29 Opus Genetics, Inc. (NASDAQ:IRD) (the "Company" or "Opus Genetics"), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with
- benzinga.com Chardan Capital Maintains Buy on Opus Genetics, Raises Price Target to $13 Chardan Capital analyst Andreas Argyrides maintains Opus Genetics (NASDAQ:IRD) with a Buy and raises the price target from $11 to $13.
- benzinga.com HC Wainwright & Co. Reiterates Buy on Opus Genetics, Maintains $8 Price Target HC Wainwright & Co. analyst Matthew Caufield reiterates Opus Genetics (NASDAQ:IRD) with a Buy and maintains $8 price target.
- benzinga.com Citizens Reiterates Market Outperform on Opus Genetics, Maintains $11 Price Target Citizens analyst Jonathan Wolleben reiterates Opus Genetics (NASDAQ:IRD) with a Market Outperform and maintains $11 price target.
- benzinga.com Opus Genetics Files Prospectus For Offering 2.679M Common Shares On Behalf Of Selling Shareholders https://www.sec.gov/Archives/edgar/data/1228627/000114036126024283/ny20075388x1_s3.htm
- benzinga.com Guggenheim Initiates Coverage On Opus Genetics with Buy Rating, Announces Price Target of $16 Guggenheim analyst Debjit Chattopadhyay initiates coverage on Opus Genetics (NASDAQ:IRD) with a Buy rating and announces Price Target of $16.
- benzinga.com Leerink Partners Initiates Coverage On Opus Genetics with Outperform Rating, Announces Price Target of $10 Leerink Partners analyst Lili Nsongo initiates coverage on Opus Genetics (NASDAQ:IRD) with a Outperform rating and announces Price Target of $10.